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The clearance of a high-risk human papillomavirus (hrHPV) infection takes time and 
requires the local presence of a strong type 1 cytokine T cell response, suggesting that 
hrHPV has evolved mechanisms to resist this immune attack. Using an unique system 
for non, newly, and persistent hrHPV infection, we show that hrHPV infection renders 
keratinocytes (KCs) resistant to the antiproliferative- and necroptosis-inducing effects of 
IFNγ and TNFα. HrHPV-impaired necroptosis was associated with the upregulation of 
several methyltransferases, including EZH2, and the downregulation of RIPK3 expres-
sion. Restoration of RIPK3 expression using the global histone methyltransferase inhib-
itor 3-deazaneplanocin increased necroptosis in hrHPV-positive KCs. Simultaneously, 
hrHPV effectively inhibited IFNγ/TNFα-mediated arrest of cell growth at the S-phase by 
downregulating IFITM1 already at 48 h after hrHPV infection, followed by an impaired 
increase in the expression of the antiproliferative gene RARRES1 and a decrease of 
the proliferative gene PCNA. Knockdown of IFITM1 in uninfected KCs confirmed its 
role on RARRES1 and its antiproliferative effects. Thus, our study reveals how hrHPV 
deregulates two pathways involved in cell death and growth regulation to withstand 
immune-mediated control of hrHPV-infected cells.
Keywords: hPV, infection, immune escape, Th1 cytokines
inTrODUcTiOn
High-risk human papillomaviruses (hrHPVs) infect undifferentiated keratinocytes (KCs) of squa-
mous epithelia. Persistent infections may lead to cancers of the anogenital region as well as of the 
head and neck (1). In order to establish a persistent and productive infection, hrHPV requires 
access to the undifferentiated KCs that make up the epithelial basal layer and have the capacity 
to divide (2). hrHPV infections can persist despite viral activity in KCs, indicating that HPV 
has developed mechanisms to evade or suppress the innate and/or adaptive immune response of 
the host. Indeed, hrHPV utilizes its viral proteins and exploits cellular proteins to interfere with 
signaling of innate immune pathways, potentially postponing the activation of an adaptive immune 
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response (3). HPV  may attenuate immune signaling at differ-
ent levels in the STAT (4–7), IRF, and NFκB pathways (8–14), 
and has also been shown to impair IFNγ and TNFα signaling 
(15). Nevertheless, T cells will become activated and migrate to 
infected sites. Studies in healthy individuals, immunosuppressed 
patients, and in patients with spontaneously or vaccine-induced 
regressions revealed an important role for a strong type 1 (IFNγ 
and TNFα)-associated HPV early antigen-specific T cell response 
in the control of HPV-infected lesions (16). However, even vac-
cines that boost viral Th1 immunity during chronic infection 
are only partially successful (17–19) with a positive clinical 
outcome only in patients with a very strong Th1 response (19, 
20), suggesting that hrHPV may have found ways to resist the 
effector cytokines of the adaptive immune system.
IFNγ is a pleiotropic cytokine that affects immune regulation, 
immune surveillance, inflammation, and tumor suppression and 
has antiviral as well as antiproliferative properties. Binding of 
IFNγ to the IFNγ receptor (IFNγR) leads to JAK1/2-mediated 
STAT1 phosphorylation, dimerization, and nuclear transloca-
tion that results in interferon-stimulated gene (ISG) expres-
sion (21). IFNγ may also induce necroptotic cell death by the 
JAK1/STAT1-dependent activation of proteins, encoded by 
interferon-stimulated genes that drive various aspects of the 
RIPK1–RIPK3 necrosome complex assembly (22), including 
the RNA-responsive protein kinase PKR, which then interacts 
with RIPK1 to trigger necroptosis (23). TNFα also regulates cell 
survival, apoptosis, or necroptosis via an intricate network of 
signals that operate downstream of TNF receptor 1 (TNFR1). 
Binding of TNF to TNFR1 leads to NFκB activation through 
cIAP-mediated ubiquitylation of RIPK1. Under circumstances 
where RIPK1 is deubiquitylated, it can associate with FADD to 
recruit and homodimerize caspase-8 leading to the induction of 
apoptosis. RIPK1 can also bind and activate RIPK3 after which 
MLKL is activated and necroptosis ensues. cFLIPL is expressed 
upon NFκB signaling (as CFLAR), heterodimerizes with cas-
pase-8 on FADD, and, as such, prevents apoptosis by abrogating 
full caspase-8 activation and necroptosis by disrupting the 
interaction between RIPK1 and RIPK3 (24).
IFNγ and TNFα are known to synergize in the suppression 
of KC proliferation (25). IFNγ induces growth arrest and dif-
ferentiation (26, 27). TNFα also induces growth arrest, but there 
are conflicting data concerning its capacity to induce cell death 
of primary KCs (25, 28). Exposure of KCs to both IFNγ and 
TNFα potently stimulates the production of nitric oxide syn-
thase (iNOS) to induce the upregulation of FasL, Fas receptor 
activation, and subsequent caspase-mediated apoptosis of KCs 
(29), an effect to which differentiated KCs are especially sensitive 
(30). However, the ability of HPV-infected undifferentiated KCs 
to resist the effects of IFNγ and/or TNFα on proliferation as well 
as the underlying mechanisms are not well understood. In this 
study, we evaluated the influence of hrHPV on the IFNγ- and 
TNFα-mediated cell growth inhibition and cell death induction 
of undifferentiated KCs by functional and biochemical assays. 
We utilized a system that resembles the natural infection with 
HPV as closely as possible, comprising of primary KCs that 
stably maintain the hrHPV genome as episomes and were shown 
to undergo the entire differentiation-dependent HPV life cycle 
in organotypic raft cultures, non-infected primary KC cultures, 
and primary KCs newly infected with authentic HPV16 virions 
(13), to show that hrHPV presence renders KCs more resistant 
to both necroptosis and the antiproliferative effects instigated 
by IFNγ and TNFα and reveal the biological mechanisms 
responsible.
MaTerials anD MeThODs
ethics statement
The use of discarded human foreskin, cervical, and vaginal 
KC tissues to develop cell lines for these studies was approved 
by the institutional review board at the Pennsylvania State 
University College of Medicine and by the institutional 
review board at Pinnacle Health Hospitals. The Medical 
Ethical Committee of the Leiden University Medical Center 
approved the human tissue sections (healthy foreskin, healthy 
cervix, and HPV16- or 18-positive cervical neoplasia) used 
for staining. All sections and cell lines were derived from 
discarded tissues and de-identified, therefore no informed 
consent was necessary.
cell culture
Primary cultures of human epithelial KCs were established 
from foreskin, vaginal, vulva, and cervical tissues as previously 
described (31) and grown in keratinocyte serum-free medium 
(EpiLife® Medium, with 60 μM calcium supplemented with HKGS 
kit, Invitrogen, Breda, The Netherlands). KCs stably maintaining 
the full episomal HPV genome following electroporation (HPV-
positive KCs) were grown in monolayer culture using E medium 
in the presence of mitomycin C-treated (Sigma-Aldrich) J2 3T3 
feeder cells (32, 33) for two passages and were then adapted to 
EpiLife® Medium for one passage before experimentation. J2 3T3 
mouse fibroblasts were cultured in Iscove’s modified Dulbecco’s 
medium supplemented with 8% fetal bovine serum, 2  mM 
l-glutamine, and 1% penicillin–streptomycin (complete IMDM 
medium) (Gibco-BRL, Invitrogen).
reagents
Recombinant human TNFα (Rhtnf-a, Invivogen/bioconnect, 
France), Recombinant Human Interferonγ (11343536, Immuno-
tools, Germany), BV-6 (S7597, Selleckchem, Netherlands), Pan 
Caspase Inhibitor Z-VAD-FMK (FMK001, R&Dsystems, USA), 
3-Deazaneplanocin A (DZNep) hydrochloride (A8182, Apexbt, 
Netherlands), necrostatin (Nec)-1s (2263-1, Biovision, CA, USA), 
Cycloheximide (CHX) solution (C4859, SIGMA, Netherlands), 
and GSK503 (S7804, Selleckchem, Netherlands).
analysis of iFngr1, TnFr1, and TnFr2 
cell surface expression
The expression of the receptors for the cytokines IFNγ and 
TNFα was analyzed by flow cytometry after staining of the 
cells with the antibodies (1:10 diluted) against IFNGRα (Mouse 
anti-human CD119-PE, clone GIR-94, BD Biosciences, Breda, 
The Netherlands), TNFR1 (mouse anti-human CD120a-PE, 
clone 16803, R&D systems, Abingdon, UK), or TNFR2 
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(mouse anti-human CD120b-PE, clone MR2.1, Invitrogen Life 
Technologies, Bleiswijk, The Netherlands). Briefly, cells were 
transferred into wells of V-bottom 96-wells plate, washed with 
ice-cold PBS + 0.5% BSA, and incubated for 10 min on ice with 
ice-cold PBS (B. Braun, Melsungen, Germany) +  0.5% bovine 
serum albumin (Sigma-Aldrich) +  10% fetal calf serum (PAA 
Laboratories, Lelystad, The Netherlands). Then, the cells were 
washed again and incubated for 30 min on ice in the dark with 
the antibody indicated. Following one wash step, the cells were 
fixed in 1% paraformaldehyde before they were acquired by BD 
Fortessa with BD FACSDiv software version 6.2 and data analyzed 
using FlowJo version 10.0.7 (Treestar, Olten, Switzerland).
hPV16 Knockdown in hPV16-Positive 
Kcs and infection of Undifferentiated 
Keratinocytes
HPV16-positive KCs were transfected with 50 nM Control or 
HPV16 E2 siRNA as previously described (13). Primary basal 
layer human foreskin KCs were infected with native HPV16 
at MOI 100 as previously described (13). Cells were washed 
and harvested, and target gene expression was assayed by 
RT-qPCR.
iFiTM1 Knockdown in 
Undifferentiated Kcs
shRNA’s were obtained from the MISSION TRC-library of 
Sigma-Aldrich (Zwijndrecht, The Netherlands). The MISSION 
shRNA clones are sequence-verified shRNA lentiviral plasmids 
(pLKO.1-puro) provided as frozen bacterial glycerol stocks 
(Luria Broth, carbenicillin at 100 μg/ml, and 10% glycerol) in E. 
coli for propagation and downstream purification of the shRNA 
clones. pLKO.1 contains the puromycin selection marker for 
transient or stable transfection. The construct against interferon-
induced transmembrane protein 1 (IFITM1) (NM_003641) was 
TRCN0000057499: CCGGCCTCATGACCATTGGATTCATCT 
CGAGATGAATCCAATGGTCATGAGGTTTTTG and the 
control was: SHC004 (MISSION TRC2-pLKO puro TurboGFP 
shRNA Control vector): CCGGCGTGATCTTCACCGACAAG 
ATCTCGAGATCTTGTCGGTGAAGATCACGTTTTT. KCs 
at ~60% confluency were transduced with lentivirus at MOI 
5–10 over night, after which medium was replaced. At least 72 h 
post-transduction, cells were harvested, washed, and plated as 
indicated and allowed to attach overnight. Cells were stimulated 
as indicated and assayed accordingly.
rna expression analyses
The micro array data (14) is accessible in the Gene Expression 
Omnibus database (accession number GSE54181). Plots were 
generated using the webtool R2: microarray analysis and visuali-
zation platform (http://r2.amc.nl).
Total RNA was isolated using the NucleoSpin RNA II 
kit (Machery-Nagel, Leiden, The Netherlands) according to 
the manufacturer’s instructions. Total RNA (0.5–1.0  μg) was 
reverse transcribed using the SuperScript III First Strand syn-
thesis system from Invitrogen. TaqMan PCR was performed 
using TaqMan Universal PCR Master Mix and pre-designed, 
pre-optimized primers and probe mix for IFITM1, GLB1, BCL-
2, Bax, RARRES1, PCNA, and GAPDH (Applied Biosystems, 
Foster City, USA). Threshold cycle numbers (Ct) were deter-
mined using the CFX PCR System (Bio-Rad, Veenendaal, The 
Netherlands), and the relative quantities of cDNA per sample 
were calculated using the ΔΔCt method using GAPDH as the 
calibrator gene.
Western Blot analysis
Polypeptides were resolved by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to a nitrocel-
lulose membrane (Bio-Rad, Veenendaal, The Netherlands). 
Immunodetection was achieved with primary antibodies against 
TRAF2 (#4724s, Cell Signaling Technology (CST), Leiden, 
Netherlands), cIAP1 (#7065p, CST), cIAP2 (#3130s, CST), 
XIAP (#14334, CST), RIPK1 (#3493, CST), cFLIP (#3210, CST), 
caspase-8 (#9746, CST), cleaved caspase-8 (#9496s, CST), FADD 
(#2782, CST), RIPK3 (#13526, CST), MLKL (#14993s, CST), 
phospho-MLKL (phospho S358; ab187091, Abcam, Cambridge, 
UK), EZH2 (612667, BD Biosciences, The Netherlands), IFITM1 
(PA5-20989, Thermo Scientific, Netherlands), Trimethyl-Histone 
H3 (Lys27) (07-449, Merk Millipore), STAT1 (#9172, CST), 
phospho-STAT1 (Tyr701, #9167, CST), β-actin (A5316, Sigma-
Aldrich, Germany), and HRP-coupled anti-mouse (#7076s, 
CST) and HRP-coupled anti-rabbit (#7074s, CST) secondary 
antibodies. Chemoluminescence reagent (#170-5060, Bio-Rad, 
Germany) was used as substrate, and signal was scanned using 
the Chemidoc and accompanying Software (Image Lab Software 
Version 5.2.1, Bio-Rad).
Proliferation assay
Keratinocytes, hrHPV +  KCs, control shRNA-expressing KCs, 
or IFITM1 shRNA-expressing KCs were seeded 5000 cell/well in 
96-well plates and allowed to attach overnight. Cells were cultured 
in presence of indicated concentrations of IFNγ and/or TNFα in 
150 μl for 96  h. 15 μl/well MTT (3-(4,5-dimethylthiazol-2-yl)-
2,3-diphenyl-2H-tetrazolum bromide) stock solution (5  mg/
ml in 0.1M PBS) was added for 3 h. When the purple formazan 
precipitate was clearly visible under the microscope, bright light 
pictures were made using an Olympus IX51 inverse fluorescence 
microscope (Olympus, Zoeterwoude, The Netherlands). Images 
were captured by ColorView II Peltier-cooled charge-coupled 
device camera (Olympus) and archived using Cell^F software 
(Olympus).
cellular Dna content analysis
The CyQuant-NF assay (C35006, ThermoFisher Scientific, 
USA), which measures cellular DNA content via fluorescent 
dye binding, was used to quantify the cell number in cultures 
treated with increasing doses of IFNγ. Briefly, control shRNA-
expressing KCs or IFITM1 shRNA-expressing KCs were seeded 
500 cell/well in 96-well plates and allowed to attach overnight. 
Cells were cultured in presence of indicated concentrations of 
IFNγ, in triplicate wells, for 96 h and then processed according 
to the protocol for adherent cells provided by the manufacturer. 
The fluorescence intensity detected is a measure for the number 
of cells present in the wells (34).
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cell cycle analysis of Keratinocytes
Following the treatment of KCs with 250 IU/ml IFNγ for 48 h, 
the cells were fixed in 70% ethanol at 4°C overnight. The fixed 
cells were washed with cold PBS and subsequently incubated 
for 30 min with 10 μg/ml RNase (#R6513, Sigma-Aldrich) and 
10  μg/ml propidium iodide (P4170, Sigma-Aldrich) staining. 
Cell cycle was detected by flow cytometry (BD Accuri™ C6, BD 
biosciences, The Netherlands) and analyzed using FlowJo v10.0.8.
sYTOX green Dead cell assay
Replicate cultures of cells were plated in 6-well tissue culture 
plates. Following the indicated treatments, all adhering and 
floating cells were collected with TrypLE™ Express Enzyme 
(12604-021, Thermofisher). The cells were washed with HBSS 
(14025-092, Thermofisher) once and then incubated with 5 μM 
SYTOX® Green Nucleic Acid Stain (S7020, Thermofisher) in 
absence or presence of 1 μg/ml DAPI (D9542, Sigma-Aldrich) 
at 20°C for 30 min. The cells were washed with HBSS and mixed 
with VECTASHIELD antifade mounting medium (Vectorlabs 
H-1000). A 30-μl cell suspension was added to a glass section 
slide and examined by fluorescence microscopy. Non-DAPI 
stained cells were detected by flow cytometry (BD Accuri™ C6) 
and analyzed using FlowJo v10.0.8.
statistics
Statistical analysis was performed using GraphPad Prism version 
6.02. P values were determined using Welch-corrected unpaired 
t-tests or one-way ANOVA Tukey’s multiple comparisons 
test. Ns: no significance. *P <  0.05, **P <  0.01, ***P <  0.001, 
****P < 0.0001.
resUlTs
hPV-infected Kcs have an altered 
expression of genes related to 
necroptosis and Proliferation in response 
to iFnγ and TnFα stimulation
We previously reported our validated microarray in which four 
independent uninfected KC and four independent hrHPV-
infected KC cultures were stimulated with control or IFNγ 
(14, 31). Analysis of marker genes in this array for necroptosis 
(RIPK3, MLKL), proliferation (RARRES1, PCNA), intrinsic 
apoptosis (BCL-2, BAX), extrinsic apoptosis (FADD, CFLAR), 
and senescence (GLB1, DEP1) revealed that hrHPV infection 
was specifically associated with changes in the genes associated 
with necroptosis and proliferation (Figure 1A). RIPK3, a crucial 
regulator of necroptosis, and its downstream partner MLKL (35) 
were both downregulated in IFNγ-stimulated hrHPV-infected 
KCs (Figure  1A). Furthermore, the increase in RARRES1, a 
marker for antiproliferation (36, 37), and the decrease in PCNA, 
a marker of proliferation, observed in KCs treated with IFNγ 
for 24 h was not seen in hrHPV-positive KCs where expression 
of these genes remained almost unaltered (Figure  1A). These 
data suggest that hrHPV-infected KCs can resist the growth 
regulatory effects of IFNγ and/or the combination of IFNγ 
and TNFα. Uninfected KCs and hrHPV-infected KCs express 
the IFNγ receptor 1 (IFNGR1), and the TNFα receptors 1 
and 2 (TNFR1 and TNFR2) at the cell surface enabling them 
to respond to these cytokines (Figure S1A in Supplementary 
Material). When these cells were seeded into 96-well plates 
and treated for 4  days with increasing doses of IFNγ and/or 
TNFα, the growth of uninfected KCs was greatly affected by 
IFNγ in a dose-dependent manner while hrHPV-positive KCs 
were much more resistant to growth inhibition and still able to 
expand to a confluent cell layer (Figure S1B in Supplementary 
Material). TNFα in itself appeared not to affect the growth of 
uninfected or HPV-infected KCs, but, when combined with 
IFNγ, it exaggerated the reduction in cell density (Figure S1B 
in Supplementary Material). To confirm these results, KCs were 
harvested after IFNγ/TNFα stimulation, and the gene expression 
of the previously indicated markers indicative for proliferation, 
senescence, apoptosis, and necroptosis were determined by 
RT-qPCR (Figure 1B). The qPCR showed that RIPK3 is lower in 
hrHPV-infected KCs, both at the basal level and after treatment, 
while the effect on MLKL was less pronounced. Moreover, the 
increase in RARRES1 and downregulation of PCNA was much 
lower in treated hrHPV-infected KC than in non-infected KCs 
(Figure  1B). Similar to the microarray, the marker genes for 
intrinsic and extrinsic apoptosis as well as senescence did not 
overtly differ between KCs and hrHPV-positive KCs. Together, 
our results show that specifically the necroptosis-associated gene 
RIPK3 and the antiproliferative gene RARRES1 were expressed 
lower in hrHPV-positive KCs. This suggests that the maintained 
proliferation of hrHPV-infected undifferentiated KCs during 
IFNγ and/or TNFα treatments is associated with a resistance 
to cell death at the level of necroptosis and by resistance to 
proliferation arrest, but less likely to be regulated at the level of 
senescence or apoptosis.
hPV suppresses necroptosis by 
Downregulating riPK3 expression
Programed cell death knows two major regulatory pathways: 
caspase-dependent apoptosis and RIP kinases-associated 
necroptosis (38). To investigate the effects of hrHPV on these 
pathways, we analyzed the expression of the proteins TRAF2, 
cIAP1, cIAP2, XIAP, FLIP, CYLD, caspase-8, FADD, RIPK1, 
RIPK3, and MLKL, involved in formation of the apoptotic or 
necroptotic signaling complexes (38) at several different time 
points after IFNγ/TNFα stimulation (Figure  2). We found a 
consistent difference between KCs and hrHPV-positive KCs 
with respect to cIAP2, the expression of which was strongly 
upregulated at both the protein and transcript level by IFNγ/
TNFα stimulation in hrHPV-positive KCs only (Figures 2A,D). 
The cytokine-stimulated expression of TRAF2 seemed to be 
higher in hrHPV-positive KCs, but this was not confirmed at 
the transcript level (Figures  2A,D). Analysis of the apoptotic 
(FLIP, CYLD, caspase-8, FADD) or necroptotic (RIPK1, RIPK3, 
MLKL) proteins revealed that the levels of FADD were consist-
ently upregulated in hrHPV-positive KCs in response to IFNγ/
TNFα treatment. Again, this was not confirmed at the transcript 
level (Figures 2B,D). Similarly, there was a hint that cFLIP was 
upregulated at the protein level, but not at the transcript level 
(Figures 2B,D). In addition, there was no difference between the 
FigUre 1 | hPV-infected Kcs display an altered expression of genes related to necroptosis and proliferation. (a) Microarray gene expression values for 
RIPK3, MLKL, RARRES1, PCNA, BCL-2, BAX, FADD, CFLAR, GLB1, and DEP1 of four independent uninfected KCs and four independent hrHPV + KCs, 
stimulated with IFNγ for 0 or 24 h, represented in a box plot. The box represents the 25th and 75th percentiles, the median is indicated with a horizontal line within 
the box, and the whiskers represent the minimum and maximum. ***P < 0.001 and ****P < 0.0001. (B) RT-qPCR of RIPK3, MLKL, RARRES1, PCNA, BCL-2, BAX, 
FADD, CFLAR, GLB1, and DEP1 in uninfected KCs and HPV16 + KCs following treatment with 50 IU/ml IFNγ and 30 ng/ml TNFα for 24 h. Gene expression was 
normalized against GAPDH mRNA levels and standardized against the non-stimulated uninfected KCs. Similar results were observed in two independent 
experiments. ****P < 0.0001.
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(a–c) Two independent uninfected KC cultures (HVK#1, HVK#2) and two HPV16 + KC cultures (HVK16, HPV16) were stimulated with 50 IU/ml IFNγ and 30 ng/
ml TNFα for the indicated times. The protein expression levels of (a) TRAF2, cIAP1, cIAP2, XIAP, RIP1; (B) FLIP, CYLD, caspase-8 (57 kD), cleaved caspase-8 
(41 kD, 43 kD), FADD; and (c) RIPK3, MLKL and MLKL-phospho S358 as detected by Western blotting (WB) in whole cell extracts. β-actin served as loading 
control. (D) Two independent uninfected KC cultures (HVK#1, HVK#2) and two HPV16 + KC cultures (HVK16, HPV16) were stimulated with 50 IU/ml IFNγ and 
30 ng/ml TNFα for 24 h after which the expression levels of cIAP2, FADD, RIPK3, CFLAR, MLKL, and TRAF2 were determined by RT-qPCR. Gene expression 
was normalized against GAPDH mRNA levels and standardized against the non-stimulated HVK#1. Similar results were observed in two independent 
experiments. (e) HPV16 E2 expression in HPV + KCs transfected with control siRNA (siControl) or siRNA targeting HPV16 E2 (siE2) stimulated with or without 
50 IU/ml IFNγ and 30 ng/ml TNFα for 24 h. E2 expression was analyzed by RT-qPCR. Gene expression was normalized against GAPDH mRNA levels and 
standardized against siControl. Similar results were observed in three independent experiments. ***P < 0.001 and ****P < 0.0001. (F) Expression of cIAP2, FADD, 
and RIPK3 in hrHPV + KCs transfected with control siRNA (siControl) or siRNA targeting HPV16 E2 (siE2) stimulated with or without 50 IU/ml IFNγ and 30 ng/ml 
TNFα for 24 h. Gene expression was normalized against GAPDH mRNA levels and standardized against siControl. Similar results were observed in two 
independent experiments. *P < 0.05, ****P < 0.0001.
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different KCs in the expression caspase-8 or in the expression of 
partially cleaved caspase-8 (43 kD) after IFNγ/TNFα treatment 
(Figure  2B). Fully cleaved caspase-8 (18  kD and 10  kD) was 
not observed in these blots, unless KCs and hrHPV + KCs were 
treated with cyclohexamide, which fosters apoptosis by promot-
ing full caspase-8 activation via the elimination of c-FLIP (39) 
(Figure S2 in Supplementary Material). Importantly, RIPK3 was 
downregulated significantly at the protein level and transcript 
level by hrHPV (Figures 2C,D). Note that, in hrHPV-positive 
KCs, the increase in phosphorylated MLKL parallels that of 
MLKL itself and does not reflect a specific increase in MLKL 
phosphorylation (Figure 2C). Notably, the expression of many 
of the proteins in the apoptotic and necroptotic signaling com-
plexes could be increased by either IFNγ or TNFα, but most 
often the two cytokines synergized in raising the expression of 
these proteins, in particular RIPK3 (Figure S3 in Supplementary 
Material). The expression of the other components showed a 
similar expression in non-infected or hrHPV-positive KCs or 
varied between cell lines in a non-HPV related manner. To study 
the role of HPV in the consistently changed components cIAP2, 
FADD, and RIPK3, the total HPV16 early gene expression was 
knocked down by introduction of siRNA against HPV16 E2 in 
hrHPV + KCs (13). This resulted in the reduction of HPV16 gene 
expression in non- and IFNγ/TNFα-stimulated hrHPV +  KC 
(Figure 2E) as well as in the upregulation of RIPK3 and unex-
pectedly also of cIAP2, while there was no change in FADD 
(Figure 2F). IFNγ/TNFα stimulation augmented the expression 
of cIAP2 and RIPK3 in KCs when the polycistronic mRNA of 
HPV16 was knocked down (Figure  2F). These data indicate 
that only the altered expression of RIPK3, but not that of cIAP2 
and FADD, can be fully accounted for by an infection of KCs 
with hrHPV and suggest that hrHPV might impair IFNγ- and 
TNFα-induced necroptosis.
To test this, KCs and hrHPV-positive KCs were stimulated for 
48 h with IFNγ and TNFα in the presence of the Smac mimetic 
BV6 and caspase inhibitor zVAD-fmk in order to promote 
necroptosis (40), and cell death was analyzed with SYTOX 
green dead cell stain. While about 80% of the non-infected KCs 
were killed, a significantly lower percentage, less than 40%, of 
the hrHPV + KCs died within this 48-h time frame (Figure 3). 
Consistent with necroptosis, cell death was completely blocked 
when the RIP kinase 1 inhibitor Nec-1s (41) was present during 
stimulation (Figure S4 in Supplementary Material). Together, 
these results show that hrHPV-infected KCs can escape from 
IFNγ/TNFα-induced necroptosis by downregulating the basal 
and cytokine-induced expression of RIPK3.
riPK3 Downregulation and resistance 
to necroptosis involves histone 
Methyltransferases Overexpressed 
in hrhPV-infected Kcs
In many cancer cell lines, the expression of RIPK3 is lost due 
to genomic methylation near its transcriptional start site (42). 
Recently, it was reported that the methyltransferase EZH2 was 
overexpressed in HPV16 E6- and E7-transformed KCs (43). Since 
EZH2 is a core component of polycomb-repressive complex 2 
(PRC2) and plays a role in promoter-targeted transcriptional 
FigUre 3 | hPV increases the resistance of Kcs to necroptosis. (a) The two independent uninfected KC cultures (HVK#1, HVK#2) and two HPV16 + KC 
cultures (HVK16, HPV16) were stimulated with 250 IU/ml IFNγ, 250 ng/ml TNFα, 5 μM BV6, and 20 μM zVAD-fmk as indicated for 48 h. All cell nuclei were labeled 
with DAPI (blue fluorescence). Dead cells were stained using SYTOX green dead cell stain resulting in green fluorescent nuclei of dead cells. (B) The number of dead 
cells among all cells were counted in multiple fields. The percentage of cell death was calculated. P values were determined using one-way ANOVA Tukey’s multiple 
comparisons test. In the group of IFNγ + TNFα + BV6 + z-VAD-fmk, HVK#1 vs. HPV16, P < 0.01; HVK#1 vs. HVK16, P < 0.001; HVK#2 vs. HPV16, P < 0.05; 
HVK#2 vs. HVK16, P < 0.05.
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repression (44), we hypothesized that EZH2 may also be involved 
in repressing the expression of RIPK3. Western blot analysis and 
RT-qPCR of primary KCs and hrHPV-infected KCs revealed 
that both gene and protein expression of EZH2 was higher at the 
basal level and after IFNγ/TNFα stimulation in hrHPV + KCs 
(Figures 4A,B). As expected (44), hrHPV-infected KCs display 
a higher methylation of H3K27 at the basal level (Figure S5A 
in Supplementary Material). Knockdown of the polycistronic 
mRNA of HPV16 in hrHPV16-positive KCs resulted in lower 
EZH2 protein levels indicating that EZH2 overexpression was 
induced by hrHPV in KCs (Figure  4C). This effect was even 
more pronounced after IFNγ/TNFα stimulation fitting with the 
observation that also the expression of the viral genes was fur-
ther downregulated (Figure 2E). The use of 3-deazaneplanocin 
A (DZNep), an inhibitor of S-adenosylmethionine-dependent 
methyltransferase, is known to effectively deplete cellular levels of 
the PRC2 components, including EZH2 (45). Indeed, treatment 
of the hrHPV + KCs with DZNep resulted in a dose-dependent 
decrease in EZH2 protein levels (Figure  4D), decreased of 
H3K27 methylation (Figure S5B in Supplementary Material), 
and the concomitant increase in RIPK3 at the protein and gene 
expression level (Figures 4D,E). Treatment of hrHPV + KCs with 
the catalytic EZH2 inhibitor GSK503 did not have a clear effect on 
the expression of RIPK3 (Figure S5C in Supplementary Material), 
suggesting that the hrHPV-induced overexpression of EZH2 is 
indirectly responsible for suppressing RIPK3-mediated necrop-
tosis. It should be noted that DZNep has been reported to func-
tion as a global histone methylation inhibitor (46). We, therefore, 
analyzed the expression of other methyltransferases and found 
that, in addition to EZH2, eight other methyltransferases were 
expressed at a significantly higher level in hrHPV + KCs (Figures 
S5D,E in Supplementary Material). Potentially, these methyl-
transferase may also play a role in downregulating the expression 
of RIPK3. To test if methyltransferases where involved in sup-
pressing RIPK3-mediated necroptosis, KCs and hrHPV + KCs 
again were stimulated with IFNγ/TNFα, BV6, and zVAD-fmk, 
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FigUre 4 | high-risk hPV-infected Kcs overexpress eZh2 and downregulates riPK3 and to resist necroptosis. (a) Two independent uninfected KC 
cultures (HVK#1, HVK#2) and two HPV16 + KC cultures (HVK16, HPV16) were stimulated with 50 IU/ml IFNγ and 30 ng/ml TNFα for the indicated times following 
the protein levels of EZH2 as detected by Western blotting (WB) in whole cell extracts. β-actin served as loading control. (B) Two independent uninfected KC 
cultures (HVK#1, HVK#2) and two HPV16 + KC cultures (HVK16, HPV16) were stimulated with 50 IU/ml IFNγ and 30 ng/ml TNFα for 24 h after which the 
expression levels of EZH2 was determined by RT-qPCR. Gene expression was normalized against GAPDH mRNA levels and standardized against the non-
stimulated uninfected KC culture HVK#1. (c) The protein expression level of EZH2 was analyzed in HPV16 + KCs (HPV16) transfected with control siRNA (siControl) 
or siRNA targeting HPV16 E2 (siE2) and stimulated with or without 50 IU/ml IFNγ and 30 ng/ml TNFα for 24 h, using Western blotting (WB) in whole cell extracts. 
β-actin served as loading control. (D) The protein expression levels of EZH2 and RIPK3 were analyzed in the two independent hrHPV + KCs (HVK16, HPV16) 72 h 
after pharmacological depletion of EZH2 by increasing doses of 3-deazaneplanocin (DZNeP). (e). The gene expression level of RIPK3 in 10 μM DZNeP-treated 
HVK16 and HPV16 hrHPV + KCs after 72 h. Gene expression was normalized against GAPDH mRNA levels and standardized against the non-treated HVK16. 
**P < 0.01, ****P < 0.0001. (F,g) Two hrHPV + KCs (HVK16, HPV16) were treated with or without 10 μM DZNeP. After 24 h, the cells were treated with 250 IU/ml 
IFNγ, 250 ng/ml TNFα, 5 μM BV6, 20 μM zVAD-fmk, and/or 20 μM Nec-1s as indicated for 48 h. The percentage of dead cells, indicated by the cells stained 
positive by SYTOX green dead cell stain, was measured by flow cytometry. (F) Example of analysis by flow cytometry. (g) The percentage of cell death measured for 
each treatment was plotted for both hrHPV + KC cultures. **P < 0.05.
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but, now, either in the absence or presence of DZNep. Cell death 
was determined both by flow cytometry in order to analyze larger 
numbers of cells (Figure 4F) and by immunofluorescence in cell 
cultures (Figure S6 in Supplementary Material). Clearly, the 
presence of DZNep increased the BV6/zVAD-fmk/IFNγ/TNFα-
induced percentage of dead cells. Cells died by necroptosis, since 
cell death could be blocked by Nec-1s (Figures 4F,G; Figure S6 in 
Supplementary Material).
Thus, by upregulating the expression of histone methyltrans-
ferases, thereby effectively decreasing the basal levels of RIPK3, 
hrHPV increases the immune resistance of KCs to IFNγ/TNFα-
stimulated necroptotic cell death.
The antiproliferative effects of iFnγ in Kcs 
are counteracted by hrhPV through 
Downregulation of interferon-induced 
Transmembrane Protein 1
Our initial analyses suggested that hrHPV-infected KCs resisted 
immune-controlled cell growth not only via impairment of 
necroptosis but also by interfering with regulation of proliferation, 
exemplified by a lower increase in RARRES1 and downregulation 
of PCNA (Figure 1). Indeed, stimulation of non-infected KCs and 
hrHPV + KCs with a high dose of IFNγ affects the growth of non-
infected KCs but not hrHPV + KCs (Figure 5A). Furthermore, 
FigUre 5 | high-risk hPV resists the antiproliferative effects of iFnγ. (a) Undifferentiated KCs (HVK#1) and HPV16 + KCs (HVK16) were treated with 
indicated doses of IFNγ for 72 h after which cell confluency was monitored by phase-contrast microscopy as a measure of proliferation. Microscopy pictures (4×, 
10×, and 20× magnifications). (B,c) The proliferation of undifferentiated KC (HVK#2) and HPV16 + KC (HPV16) treated with 250 IU/ml IFNγ for 48 h was analyzed 
by examination of the proportion of DNA that was present in the various phases (G1, S, G2/M) of cell growth using PI staining and flow cytometry. (B) Example of 
flow cytometric analysis. The DNA content of 10,000 cells was analyzed. (c) The fold-change in the percentage of cells in the S-phase of treated cells over 
non-treated cells of n = 3 experiments is shown. **P < 0.01. (D) The protein levels of STAT1 and phosphorylated STAT1 at Tyr701 protein levels in undifferentiated 
KCs and HPV16 + KCs harvested at indicated time points after stimulation with 50 IU/ml IFNγ as measured by WB is shown. β-actin served as loading control. 
(e) Expression of STAT1 in HPV16 + KCs transfected with control siRNA (siControl) or siRNA targeting HPV16 E2 (siE2) stimulated with or without 50 IU/ml IFNγ 
and 30 ng/ml TNFα for 24 h. Gene expression was normalized against GAPDH mRNA levels and fold-change over non-stimulated siControl was calculated. 
****P < 0.0001, ***P < 0.001. (F) Gene expression analysis of RARRES1 and PCNA in undifferentiated KCs and HPV16 + KCs treated with 50 IU/ml IFNγ and 
30 ng/ml TNFα for 24 h. Gene expression was normalized against GAPDH mRNA levels and fold-change over control was calculated.
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analysis of the cell cycle using flow cytometry and propidium 
iodide DNA staining, showed that treatment of KCs with IFNγ 
caused a 50% reduction in the S-phase while it hardly affected 
hrHPV + KCs (Figures 5B,C).
IFNγ signaling requires STAT1 and it has been reported 
that HPV can lower STAT1 expression and protein levels 
in KCs (4–7), potentially explaining the resistance to IFNγ 
treatment. Indeed, hrHPV-positive KCs displayed a lower 
FigUre 6 | high-risk hPV-infected Kcs downregulate iFiTM1 to suppress the expression of RARRES1 and to maintain proliferation. (a) Microarray 
gene expression values for IFITM1 in four independent uninfected KCs and four independent hrHPV + KCs represented in a box plot. *P < 0.05. (B) The expression 
level of IFITM1 in HVK#1, HVK#2, HVK16, and HPV16 determined by RT-qPCR. Gene expression was normalized against GAPDH mRNA levels. (c) The expression 
level of IFITM1 in KCs infected with mock or native HPV16 virions for 1 or 2 days, respectively. (D) Expression of IFITM1 in HPV16 + KCs transfected with control 
siRNA (siControl) or siRNA targeting HPV16 E2 (siE2) stimulated with or without 50 IU/ml IFNγ and 50 ng/ml TNFα for 24 h. Gene expression was normalized 
against GAPDH mRNA levels and fold-change over non-stimulated siControl was calculated. *P < 0.05, ****P < 0.0001. (e, F) The expression of IFITM1 in 
undifferentiated KCs and HPV16 + KCs stimulated with 50 IU/ml IFNγ and/or 50 ng/ml TNFα for 24 h. Gene expression was normalized against GAPDH mRNA 
levels and fold-changes over (e) control-stimulated undifferentiated KCs or over (F) control-stimulated HPV16 + KCs were calculated and depicted. (g) IFITM1 
protein levels in KC and HPV16 + KC stimulated with 0, 100, or 1000 IU/ml IFNγ, as measured by WB. β-actin served as loading control. (h) IFITM1 expression in 
control and IFITM1 knockdown uninfected KCs as measured by RT-qPCR. Gene expression was normalized against GAPDH mRNA levels and fold-change over 
siControl was calculated. (i) Control and IFITM1 knockdown KCs were stimulated with 50 IU/ml IFNγ and/or 50 ng/ml TNFα for 24 h before the expression of 
RARRES, PCNA, and IFITM1 was measured by RT-qPCR. Gene expression was normalized against GAPDH mRNA levels and fold-change over non-stimulated 
shControl was calculated.
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expression of STAT1 at the protein level (Figure 5D; Figure S7 
in Supplementary Material), and this was due to the presence of 
hrHPV as knockdown of the polycistronic viral mRNA resulted 
in a higher STAT1 expression (Figure  5E). Notably, cytokine 
stimulation also upregulated STAT1 expression (Figure  5E), 
and IFNγ stimulation resulted in high levels of phosphorylated 
STAT1 in hrHPV + KCs (Figure 5D), indicating that HPV may 
repress the basal levels of STAT1 but it does not overtly interfere 
with STAT1 signaling per  se. This also explains why IFNγ, 
especially at higher concentrations and in combination with 
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TNFα, is able to stimulate the expression of the antiprolifera-
tive gene RARRES1 and downregulation of the proliferative 
gene PCNA (Figure  5F), albeit that the combinatory effects 
of IFNγ and TNFα were more pronounced on non-infected 
KCs (Figure  5F).
Interferon-induced transmembrane protein 1 (IFITM1) 
plays an essential role in the antiproliferative action of IFNγ 
(47), making it a potential target for hrHPV. Re-analysis of 
the data from one of our earlier validated microarrays, in 
which the basal expression of genes measured in different 
uninfected and hrHPV-infected KCs was compared in the 
absence of IFNγ stimulation (31), showed that IFITM1 expres-
sion is downregulated in HPV-positive KCs (Figure 6A). This 
was confirmed by RT-qPCR (Figure  6B). To show that the 
expression of IFITM1 was genuinely altered by the presence of 
hrHPV in KCs, undifferentiated KCs were infected with native 
HPV16 virions resulting in a reduced expression of IFITM1 
(Figure 6C). Reciprocally, the knockdown of total HPV16 early 
gene expression in hrHPV + KCs resulted in the upregulation 
of IFITM1 (Figure  6D). IFNγ induces de novo synthesis of 
IFITM1 for which STAT1 is required (48–51). Indeed, IFNγ 
stimulation of uninfected KCs resulted in approximately 
fourfold increase in IFITM1 after 24 h (Figure 6E). Strikingly, 
IFNγ stimulation of hrHPV + KCs resulted in a much stronger 
relative increase of IFITM1 levels (Figure 6F), albeit that these 
levels still remained lower than those measured in uninfected 
KCs (Figure  6E). IFITM1 protein levels in IFNγ-stimulated 
KCs and hrHPV +  KCs confirmed the gene expression data 
(Figure 6G). These data indicated that hrHPV predominantly 
regulates the expression of IFITM1 at the basal level but less at 
the level of IFNγ-mediated induction of IFITM1 gene expres-
sion. Interestingly, the hrHPV +  KCs with the highest basal 
IFITM1 protein expression also showed the highest STAT1 
levels (Figure S7 in Supplementary Material). TNFα did not 
influence IFITM1 expression (Figures 6E,F).
To study the effects of IFITM1 on KC proliferation in a set-
ting where all additional influences of HPV are ruled out (52, 
53), IFITM1 was knocked down in uninfected KCs (Figure 6H). 
The KCs were stimulated with IFNγ or IFNγ/TNFα. The basal 
level of RARRES1 was lower in IFITM1 knocked-down KCs, 
and its IFNγ-induced expression was clearly affected when KCs 
were stimulated with a low concentration of IFNγ (Figure 6I). 
A higher concentration of IFNγ overcame the effect of IFITM1 
knockdown on the expression of RARRES1. In addition, IFITM1-
knockdown KCs displayed a less strong downregulation of PCNA 
upon IFNγ stimulation (Figure 6I). The less pronounced effects 
on RARRES1 and PCNA at the higher IFNγ concentrations used 
was probably due to the fact that upon IFNγ stimulation still an 
increase in IFITM1 could be observed in IFITM1 knockdown KCs 
(Figure  6I). In addition, control shRNA-transduced KCs were 
less resistant than IFITM1 knockdown KCs to the antiprolifera-
tive effects of IFNγ and the combination of IFNγ and TNFα when 
cell confluency was monitored by phase-contrast microscopy or 
cell number was quantitated by a DNA-based proliferation assay 
(Figures S8A,B in Supplementary Material). Thus, HPV is able to 
resist IFNγ-mediated arrest of proliferation by lowering the basal 
levels of IFITM1.
DiscUssiOn
In most cases, the immune system succeeds in controlling hrHPV 
infections but this process takes time and requires the presence of 
strong IFNγ and TNFα-associated HPV-specific T cell responses 
(16). Here, we show that hrHPV-infected KCs resist the immune 
system by interfering with the regulation of intracellular growth 
and cell death programs of infected cells. Under normal cir-
cumstances, these would be activated in response to the effector 
molecules of the adaptive immune system and function as a host 
defense mechanism to control viral spread (54). Using a unique 
in  vitro model, we showed that hrHPV infection renders KCs 
resistant to IFNγ/TNFα-induced necroptosis and arrest of cell 
growth. HrHPV infection is associated with the upregulation of 
nine methyltransferases, including EZH2, and downregulation 
of the expression of RIPK3, which results in an impaired induc-
tion of necroptosis by IFNγ/TNFα stimulation. Use of DZNep, 
a global inhibitor of methyltransferases and a pharmacological 
compound that depletes EZH2 (45, 46), restored the expression 
of RIPK3 and the sensitivity of hrHPV-infected KCs to IFNγ/
TNFα-mediated necroptosis. Use of the catalytic EZH2 inhibitor 
GSK503 did not restore RIPK3 expression, suggesting that either 
EZH2 is indirectly responsible for suppressing RIPK3-mediated 
necroptosis or that one or more of the other overexpressed 
methyltransferases are involved in the downregulation of RIPK3. 
Furthermore, hrHPV effectively downregulated the basal expres-
sion of the negative regulator of cell growth IFITM1, resulting 
in an impaired IFNγ-mediated increase in the expression of the 
antiproliferative RARRES1 gene and decrease of the proliferative 
gene PCNA as well as impaired arrest of cells in the S-phase. 
Knockdown of IFITM1 with siRNA in normal KCs recapitulated 
the effects on RARRES1 and PCNA expression and cell prolifera-
tion observed in hrHPV + KCs.
Apoptosis and necroptosis play an important role in control-
ling viral infections (54). We did not observe any HPV-induced 
differences in the expression of caspase-8, FLIP, or FADD, nor 
did we observe differences in cleavage of caspase-8 upon stimula-
tion with IFNγ and TNFα. Notably, stimulation with IFNγ and 
TNFα did not lead to activation of caspase-8, reflected by the 
absence of fully cleaved caspase-8 in undifferentiated normal 
or hrHPV-positive KCs. However, upon differentiation, KCs 
become sensitive to Fas- and caspase-8-mediated apoptosis fol-
lowing stimulation with IFNγ and TNFα (29, 30). In contrast, 
stimulation of undifferentiated KCs did result in necroptosis 
following an increase of RIPK3, most notably when both IFNγ 
and TNFα were used. The induction of necroptosis has shown 
to be important for the control of vaccinia virus (55) and herpes 
simplex virus type 1 (56). Consequently, viruses have developed 
strategies to resist this immune control mechanism. The murine 
cytomegalovirus expresses the M45-encoded inhibitor of RIP 
activation (vIRA) that targets RIPK3 and disrupts RIPK1–RIPK3 
interactions characteristic for necroptosis (57). Rather than by 
interrupting necroptosis, hrHPV prevents the formation of the 
necrosome by reducing the levels of RIPK3 via the upregulation 
of histone methyltransferases.
The production of new HPV particles requires prolifera-
tion and differentiation of infected basal KCs. An arrest in cell 
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proliferation, therefore, is an effective means to control viral 
infection. IFITM1 plays an essential role in the antiproliferative 
action of IFNγ (47), thus lowering its expression – as observed in 
hrHPV-infected KCs – may allow viral escape. Indeed, hepatitis 
C virus was found to decrease the expression of IFITM1 via 
the upregulation of mIR-130a in order to sustain its replica-
tion (58). We showed that the basal expression of IFITM1 is 
downregulated in hrHPV +  KCs, but its downstream partner 
RARRES1 is not. This might be explained by the fact that the 
basal expression of RARRES1 in uninfected KCs is already 
low. The IFNγ-induced increase in expression of IFITM1 and 
RARRES1 requires signaling via the IFNGR1 and STAT1. 
Overexpression of EZH2 has been reported to suppress the 
expression of IFNGR1 in MYC- transformed cells but not 
phosphatidylinositol 3-kinase (PI3K)-transformed cells, despite 
the fact that in both types of transformed cells EZH2 was 
overexpressed (59). Notwithstanding the ectopic expression of 
EZH2 in hrHPV-positive KCs, there were no specific differences 
in the expression of IFNGR1 between non-infected and hrHPV-
positive cells. This is in line with the observation that the PI3K 
pathway is a major target for the hrHPV proteins (59, 60) and 
suggests that the overexpression of EZH2 does not play a role in 
the escape of hrHPV-positive cells at this level. It was previously 
reported that the HPV early proteins E6 and E7 downregulate 
the expression of STAT1 (4–6). Our data confirm that infection 
with hrHPV decreases basal STAT1 protein levels in KCs but 
also show that hrHPV does not interfere with IFNγ-induced 
STAT1 activation per  se, as reflected by STAT1 phosphoryla-
tion and increase in RARRES1 and IFITM1 expression. Still, as 
total STAT1 levels are lower in hrHPV + KCs, the reduced total 
amount of activated STAT1 may explain why in hrHPV + KCs 
the increase in RARRES1 and IFITM1 expression does not reach 
the levels observed in uninfected KCs. This is also demonstrated 
by the data showing that the effect of IFITM1 knockdown on 
proliferation of uninfected KCs is not similar to what hrHPV has 
on KCs. While the effect of IFITM1 in uninfected KCs is appar-
ent and antiproliferative, indicated by the retained expression of 
PCNA and RARRES1 in KCs stimulated with a low dose of IFNγ 
when IFITM1 was knocked down, clearly the downregulation 
of STAT1 as well as the positive growth signals as delivered by 
hrHPV (52, 53) are missing in these cells. Hence, differences in 
IFNγ-stimulated arrest of proliferation are less noticeable. This 
shows that, whereas the decreased basal level of IFITM1 is already 
providing resistance to the IFNγ-stimulated arrest of prolifera-
tion, the downregulation of STAT1 is likely to exaggerate this 
effect. Mechanistically, IFITM1 inhibits the phosphorylation of 
ERK and thereby regulates mitogen-activated protein (MAP) 
kinase signaling. Furthermore, IFITM1 mediates the de-phos-
phorylation of p53 at Thr55, resulting in increased p53 stability 
and transcriptional activity and the upregulated expression of 
p21. Consequently, there is an arrest in cell cycle progression 
and hence a stop in proliferation (47). This was also observed in 
this study and reflected by the retained PCNA expression when 
IFITM1 was knocked down in low dose IFNγ-stimulated KCs.
In conclusion, hrHPV controls proliferation by regulating the 
expression of (anti-)proliferative genes via STAT1 and IFITM1 
and resists the induction of necroptotic cell death by downregula-
tion of RIPK3 expression. This allows infected KCs to partly resist 
immune pressure by IFNγ/TNFα and explains how hrHPV can 
partially evade the effector mechanisms of the immune system, 
which may ultimately lead to progression of hrHPV-induced 
lesions.
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